peptide stability FAQ

Aliquot the remaining solution into single-use volumes and freeze at −80°C immediately. This arrests further degradation and extends usable lifespan by 3–6 months. Each aliquot should be thawed only once; repeated freeze-thaw cycles cause ice crystal formation that physically disrupts the peptide structure. Label each aliquot with the reconstitution date and freeze date. For critical experiments, run a fresh standard curve using a newly reconstituted reference vial to confirm your frozen aliquots retained expected activity.

You can't chemically modify the peptide's clearance rate post-administration without changing its structure, but you can optimize dosing timing around activity windows. Dose immediately before or after events where tissue repair signaling is most active. Post-exercise for musculoskeletal applications, or in the evening for circadian-aligned regenerative processes. The peptide's effects outlast its plasma presence by 6–12 hours due to downstream gene transcription, so strategic timing maximizes that window.

Discard it immediately. AHK-Cu in solution should be clear to faintly blue-tinted (from the copper ion). Cloudiness indicates protein aggregation or bacterial contamination; discolouration (yellow, brown, green) suggests oxidative degradation. Using degraded peptide isn't just ineffective. Oxidised copper peptides can generate reactive oxygen species that damage tissue rather than promoting repair. This is precisely why our Cognitive Function formulations include antioxidant co-factors. Copper's catalytic activity is therapeutic when controlled but destructive when unregulated.

You'll maintain therapeutic plasma levels for only 4–6 hours of each 24-hour cycle, leaving 18–20 hours below the minimum effective concentration observed in cellular studies. Split the same total dose into two administrations 10–12 hours apart. Research comparing single versus divided dosing in wound healing models shows divided protocols produce 30–40% greater collagen deposition and capillary density at equivalent total peptide exposure.